Piramal Pharma to acquire 100 percent stake in Hemmo PharmaceuticalsIllustrative image – not actual.
Piramal Pharma’s (PPL) contract development and manufacturing organisation (CDMO), Piramal Pharma Solutions (PPS), announced PPL has entered into an agreement to acquire 100 percent stake in Hemmo Pharmaceuticals (Hemmo) for an upfront consideration of Rs 775 crore and earn-outs linked to achievement of milestones. 
 
The acquisition marks PPS’ foray into development and manufacturing of peptide APIs, a capability that complements PPS’ existing service offering. Hemmo is one of the few pure-play synthetic peptide API manufacturers in global marketplace. 
 
With the addition of Hemmo’s capabilities, PPS will gain access to the growing peptide API market and enhance its ability to offer integrated services to its customers globally. 
 
Hemmo has R&D capabilities and a GMP manufacturing facility that has been inspected and deemed compliant by US, EU and Asian regulatory agencies. The company has strong expertise in both solution phase and solid phase synthesis of peptides. 
 
The acquisition is expected to add more than 250 employees to PPS, including several PhD scientists and a quality team of over 60. 
 
The acquisition agreement is subject to customary regulatory closing conditions. 
 
Kotak Mahindra Capital Company served as financial advisor and Economic Laws Practice (ELP) served as legal advisors to PPL on this transaction. 
 
Torreya Partners India served as financial advisor and Desai & Diwanji, Mumbai, served as legal advisors to Hemmo Pharmaceuticals and selling shareholders on this transaction.
← All latest storiesBack to top →